Mitochondrial dysfunction has been widely reported in several neurodegenerative disorders, including in the brains of patients with Alzheimer’s disease (AD), Parkinson’s disease, and Huntington disease. An increasing number of studies have implicated altered glucose and energy metabolism in patients with AD. There is compelling evidence of abnormalities in some of the key mitochondrial enzymes involved in glucose metabolism, including the pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes, which play a great significance role in the pathogenesis of AD. Changes in some of the enzyme activities of the mitochondria found in AD have been linked with the pathology of amyloid-β (Aβ). This review highlights the role of mitochondrial function in the production and clearance of Aβ and how the pathology of Aβ leads to a decrease in energy metabolism by affecting mitochondrial function.
ChenS, JiangQ, HuangP, HuC, ShenH, SchachnerM, ZhaoW (2020) The L1 cell adhesion molecule affects protein kinase D1 activity in the cerebral cortex in a mouse model of Alzheimer’s disease. Brain Res Bull162, 141–150.
2.
CaccamoA, MajumderS, RichardsonA, StrongR, OddoS (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem285, 13107–13120.
3.
DuY, FuM, HuangZ, TianX, LiJ, PangY, SongW, Tian WangY, DongZ (2020) TRPV1 activation alleviates cognitive and synaptic plasticity impairments through inhibiting AMPAR endocytosis in APP23/PS45 mouse model of Alzheimer’s disease. Aging Cell19, e13113.
4.
TramutolaA, TrianiF, Di DomenicoF, BaroneE, CaiJ, KleinJB, PerluigiM, ButterfieldDA (2018) Poly-ubiquitin profile in Alzheimer disease brain. Neurobiol Dis118, 129–141.
5.
TeradaT, ObiT, BunaiT, MatsudairaT, YoshikawaE, AndoI, FutatsubashiM, TsukadaH, OuchiY (2020) mitochondrial and glycolytic impairments in patients with Alzheimer disease. Neurology94, e1592–e1604.
6.
HuH, LiM (2016) Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons. Biochem Biophys Res Commun478, 174–180.
7.
DemarestTG, VarmaVR, EstradaD, BabbarM, BasuS, MahajanUV, MoaddelR, CroteauDL, ThambisettyM, MattsonMP, BohrVA (2020) Biological sex and DNA repair deficiency drive Alzheimer’s disease via systemic metabolic remodeling and brain mitochondrial dysfunction. Acta Neuropathol140, 25–47.
8.
TheureyP, ConnollyNMC, FortunatiI, BassoE, LauwenS, FerranteC, Moreira PinhoC, JoselinA, GioranA, BanoD, ParkDS, AnkarcronaM, PizzoP, PrehnJHM (2019) Systems biology identifies preserved integrity but impaired metabolism of mitochondria due to a glycolytic defect in Alzheimer’s disease neurons. Aging Cell18, e12924.
9.
PeraM, LarreaD, Guardia-LaguartaC, MontesinosJ, VelascoKR, AgrawalRR, XuY, ChanRB, Di PaoloG, MehlerMF, PerumalGS, MacalusoFP, FreybergZZ, Acin-PerezR, EnriquezJA, SchonEA, Area-GomezE (2017) Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J36, 3356–3371.
10.
van Gijsel-BonnelloM, BarangerK, BenechP, RiveraS, KhrestchatiskyM, de ReggiM, GharibB (2017) Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer’s disease: Alleviation by pantethine. PLoS One12, e0175369.
11.
GibsonGE, XuH, ChenHL, ChenW, DentonTT, ZhangS (2015) Alpha-ketoglutarate dehydrogenase complex-dependent succinylation of proteins in neurons and neuronal cell lines. J Neurochem134, 86–96.
12.
ShaerzadehF, MotamediF, KhodagholiF (2014) Inhibition of akt phosphorylation diminishes mitochondrial biogenesis regulators, tricarboxylic acid cycle activity and exacerbates recognition memory deficit in rat model of Alzheimer’s disease. Cell Mol Neurobiol34, 1223–1233.
13.
SorbiS, BirdED, BlassJP (1983) Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol13, 72–78.
14.
MastrogiacomoF, LaMarcheJ, DozicS, LindsayG, Bet-tendorffL, RobitailleY, SchutL, KishSJ (1996) Immunoreactive levels of alpha-ketoglutarate dehydrogenase subunits in Friedreich’s ataxia and spinocerebellar ataxia type 1. Neurodegeneration5, 27–33.
15.
ButterworthRF, BesnardAM (1990) Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer’s disease. Metab Brain Dis5, 179–184.
16.
TeoE, RaviS, BarardoD, KimHS, FongS, Cazenave-GassiotA, TanTY, ChingJ, KovalikJP, WenkMR, GunawanR, MoorePK, HalliwellB, TolwinskiN, GruberJ (2019) Metabolic stress is a primary pathogenic event in transgenic Caenorhabditis elegans expressing pan-neuronal human amyloid beta. Elife8, e50069.
17.
HikosakaK, YakuK, OkabeK, NakagawaT (2019) Implications of NAD metabolism in pathophysiology and therapeutics for neurodegenerative diseases. Nutr Neurosci, doi: 10.1080/1028415X.2019.1637504.
18.
Martinez-ReyesI, ChandelNS (2020) Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun11, 102.
XuY, XiaoL (2020) Efficient suppression of amyloid-beta peptide aggregation and cytotoxicity with photosensitive polymer nanodots. J Mater Chem B8, 5776–5782.
21.
KikuchiK, KidanaK, TatebeT, TomitaT (2017) Dysregulated metabolism of the amyloid-beta protein and therapeutic approaches in Alzheimer disease. J Cell Biochem118, 4183–4190.
22.
JagustW (2018) Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci19, 687–700.
23.
KaminskyYG, TikhonovaLA, KosenkoEA (2015) Critical analysis of Alzheimer’s amyloid-beta toxicity to mitochondria. Front Biosci (Landmark Ed)20, 173–197.
24.
VolgyiK, JuhaszG, KovacsZ, PenkeB (2015) Dysfunction of endoplasmic reticulum (ER) and mitochondria (MT) in Alzheimer’s disease: The role of the ER-MT cross-talk. Curr Alzheimer Res12, 655–672.
25.
ZhangZ, CuiD, ZhangT, SunY, DingS (2020) Swimming differentially affects T2DM-induced skeletal muscle ER stress and mitochondrial dysfunction related to MAM. Diabetes Metab Syndr Obes13, 1417–1428.
26.
Area-GomezE, de GroofA, BonillaE, MontesinosJ, TanjiK, BoldoghI, PonL, SchonEA (2018) A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease. Cell Death Dis9, 335.
27.
LiuD, PittaM, LeeJH, RayB, LahiriDK, FurukawaK, MughalM, JiangH, VillarrealJ, CutlerRG, GreigNH, MattsonMP (2010) The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer’s disease. J Alzheimers Dis22, 443–457.
28.
ReddyPH, TripathiR, TroungQ, TirumalaK, ReddyTP, AnekondaV, ShirendebUP, CalkinsMJ, ReddyAP, MaoP, ManczakM (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta1822, 639–649.
29.
ManczakM, AnekondaTS, HensonE, ParkBS, QuinnJ, ReddyPH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet15, 1437–1449.
30.
CrouchPJ, BlakeR, DuceJA, CiccotostoGD, LiQX, BarnhamKJ, CurtainCC, ChernyRA, CappaiR, DyrksT, MastersCL, TrounceIA (2005) Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci25, 672–679.
ReddyPH, MaoP, ManczakM (2009) Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res Rev61, 33–48.
33.
OliverD, ReddyPH (2019) Dynamics of dynamin-related protein 1 in Alzheimer’s disease and other neurodegenerative diseases. Cells8, 961.
34.
YuR, LiuT, JinSB, NingC, LendahlU, NisterM, ZhaoJ (2017) MIEF1/2 function as adaptors to recruit Drp1 to mitochondria and regulate the association of Drp1 with Mff. Sci Rep7, 880.
35.
PanesJD, GodoyPA, Silva-GrecchiT, CelisMT, Ramirez-MolinaO, GavilanJ, Munoz-MontecinoC, CastroPA, Moraga-CidG, YevenesGE, GuzmanL, SalisburyJL, TrushinaE, FuentealbaJ (2020) Changes in PGC-1alpha/ SIRT1 signaling impact on mitochondrial homeostasis in amyloid-beta peptide toxicity model. Front Pharmacol11, 709.
36.
SmallGW, ErcoliLM, SilvermanDH, HuangSC, KomoS, BookheimerSY, LavretskyH, MillerK, SiddarthP, RasgonNL, MazziottaJC, SaxenaS, WuHM, MegaMS, CummingsJL, SaundersAM, Pericak-VanceMA, RosesAD, BarrioJR, PhelpsME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A97, 6037–6042.
37.
AtamnaH, FreyWH2nd (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease. Mitochondrion7, 297–310.
38.
GaspariniL, GourasGK, WangR, GrossRS, BealMF, GreengardP, XuH (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci21, 2561–2570.
39.
GabuzdaD, BusciglioJ, ChenLB, MatsudairaP, YanknerBA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem269, 13623–13628.
40.
MurrayIV, ProzaJF, SohrabjiF, LawlerJM (2011) Vascular and metabolic dysfunction in Alzheimer’s disease: A review. Exp Biol Med (Maywood)236, 772–782.
41.
AlikhaniN, AnkarcronaM, GlaserE (2009) Mitochondria and Alzheimer’s disease: Amyloid-beta peptide uptake and degradation by the presequence protease, hPreP. J Bioenerg Biomembr41, 447–451.
42.
ZakariaA, HamdiN, Abdel-KaderRM (2016) Methylene blue improves brain mitochondrial ABAD functions and decreases Abeta in a neuroinflammatory Alzheimer’s disease mouse model. Mol Neurobiol53, 1220–1228.
ManczakM, ReddyPH (2012) Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum Mol Genet21, 5131–5146.
48.
Pahrudin ArroziA, ShukriSNS, Wan NgahWZ, Mohd YusofYA, Ahmad DamanhuriMH, JaafarF, MakpolS (2020) Comparative effects of alpha- and gamma-toco-pherol on mitochondrial functions in Alzheimer’s diseasemodel. Sci Rep10, 8962.
49.
HensleyK, HallN, SubramaniamR, ColeP, HarrisM, AksenovM, AksenovaM, GabbitaSP, WuJF, CarneyJM, LovellM, MarkesberyWR, ButterfieldDA (1995) Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem65, 2146–2156.
50.
DhitavatS, OrtizD, SheaTB, RiveraER (2002) Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: Roles of oxidative buffering and ATP levels. Neurochem Res27, 501–505.
ShiQ, XuH, YuH, ZhangN, YeY, EstevezAG, DengH, GibsonGE (2011) Inactivation and reactivation of the mitochondrial alpha-ketoglutarate dehydrogenase complex. J Biol Chem286, 17640–17648.
53.
ShaerzadehF, MotamediF, Minai-TehraniD, KhodagholiF (2014) Monitoring of neuronal loss in the hippocampus of Abeta-injected rat: Autophagy, mitophagy, and mitochondrial biogenesis stand against apoptosis. Neuromolecular Med16, 175–190.
54.
Tarasoff-ConwayJM, CarareRO, OsorioRS, GlodzikL, ButlerT, FieremansE, AxelL, RusinekH, NicholsonC, ZlokovicBV, FrangioneB, BlennowK, MenardJ, ZetterbergH, WisniewskiT, de LeonMJ (2015) Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol11, 457–470.
55.
XinSH, TanL, CaoX, YuJT, TanL (2018) Clearance of amyloid beta and tau in Alzheimer’s disease: From mechanisms to therapy. Neurotox Res34, 733–748.
56.
KimSJ, AhnJW, KimH, HaHJ, LeeSW, KimHK, LeeS, HongHS, KimYH, ChoiCY (2013) Two beta-strands of RAGE participate in the recognition and transport of amyloid-beta peptide across the blood brain barrier. Biochem Biophys Res Commun439, 252–257.
57.
TangY, LeW (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol53, 1181–1194.
58.
ThalDR (2012) The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol236, 1–5.
59.
YoonS-S, AhnJoS-M (2012) Mechanisms of amyloid-β peptide clearance: Potential therapeutic targets for Alzheimer’s disease. Biomol Ther (Seoul)20, 245–255.
DowerCM, WillsCA, FrischSM, WangHG (2018) Mechanisms and context underlying the role of autophagy in cancer metastasis. Autophagy14, 1110–1128.
62.
DengW, MaL, ZhangY, ZhouJ, WangY, LiuZ, XueY (2018) THANATOS: An integrative data resource of proteins and post-translational modifications in the regulation of autophagy. Autophagy14, 296–310.
63.
CorreiaSC, ResendeR, MoreiraPI, PereiraCM (2015) Alzheimer’s disease-related misfolded proteins and dysfunctional organelles on autophagy menu. DNA Cell Biol34, 261–273.
64.
AlgarzaeN, HebronM, MiessauM, MoussaCE (2012) Parkin prevents cortical atrophy and Abeta-induced alterations of brain metabolism: (1)(3)C NMR and magnetic resonance imaging studies in AD models. Neuroscience225, 22–34.
65.
GreeneJC, WhitworthAJ, AndrewsLA, ParkerTJ, PallanckLJ (2005) Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet14, 799–811.
BharadwajPR, MartinsRN (2020) Autophagy modulates Abeta accumulation and formation of aggregates in yeast. Mol Cell Neurosci104, 103466.
73.
LanzillottaC, Di DomenicoF, PerluigiM, ButterfieldDA (2019) Targeting mitochondria in Alzheimer disease: Rationale and perspectives. CNS Drugs33, 957–969.
74.
MaoP, ManczakM, CalkinsMJ, TruongQ, ReddyTP, ReddyAP, ShirendebU, LoHH, RabinovitchPS, ReddyPH (2012) Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer’s disease: Implications for neuroprotection and lifespan extension. Hum Mol Genet21, 2973–2990.
75.
DyskenMW, SanoM, AsthanaS, VertreesJE, PallakiM, LlorenteM, LoveS, SchellenbergGD, McCartenJR, MalphursJ, PrietoS, ChenP, LoreckDJ, TrappG, BakshiRS, MintzerJE, HeidebrinkJL, Vidal-CardonaA, ArroyoLM, CruzAR, ZachariahS, KowallNW, ChopraMP, CraftS, ThielkeS, TurveyCL, WoodmanC, MonnellKA, GordonK, TomaskaJ, SegalY, PeduzziPN, GuarinoPD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA311, 33–44.
76.
LeeJ, KimY, LiuT, HwangYJ, HyeonSJ, ImH, LeeK, AlvarezVE, McKeeAC, UmSJ, HurM, Mook-JungI, KowallNW, RyuH (2018) SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer’s disease. Aging Cell17, e12679.
77.
YoungML, FranklinJL (2019) The mitochondria-targeted antioxidant MitoQ inhibits memory loss, neuropathology, and extends lifespan in aged 3xTg-AD mice. Mol Cell Neurosci101, 103409.
